Fiche du document
6 mai 2021
- doi: 10.3390/genes12050695
- issn: 2073-4425
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3390/genes12050695
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34066437
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2073-4425
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_EF75CA328A1A1
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Medical examinations (Diagnosis) Diseases--Diagnosis Diseases--Testing Examinations, Medical (Diagnosis) Medical diagnosis Medical tests (Diagnosis) Grown-ups Adults GrownupsCiter ce document
J.M. Good et al., « NGS-Based Diagnosis of Treatable Neurogenetic Disorders in Adults: Opportunities and Challenges. », Serveur académique Lausannois, ID : 10.3390/genes12050695
Métriques
Partage / Export
Résumé
The identification of neurological disorders by next-generation sequencing (NGS)-based gene panels has helped clinicians understand the underlying physiopathology, resulting in personalized treatment for some rare diseases. While the phenotype of distinct neurogenetic disorders is generally well-known in childhood, in adulthood, the phenotype can be unspecific and make the standard diagnostic approach more complex. Here we present three unrelated adults with various neurological manifestations who were successfully diagnosed using NGS, allowing for the initiation of potentially life-changing treatments. A 63-year-old woman with progressive cognitive decline, pyramidal signs, and bilateral cataract was treated by chenodeoxycholic acid following the diagnosis of cerebrotendinous xanthomatosis due to a homozygous variant in CYP27A1. A 32-year-old man with adult-onset spastic paraplegia, in whom a variant in ABCD1 confirmed an X-linked adrenoleukodystrophy, was treated with corticoids for adrenal insufficiency. The third patient, a 28-year-old woman with early-onset developmental delay, epilepsy, and movement disorders was treated with a ketogenic diet following the identification of a variant in SLC2A1, confirming a glucose transporter type 1 deficiency syndrome. This case study illustrates the challenges in the timely diagnosis of medically actionable neurogenetic conditions, but also the considerable potential for improving patient health through modern sequencing technologies.